introduction
Pancreatic cancer is the fifth most frequent cause of cancer death in high-income countries [1] and is one of the most aggressive neoplasms with a 5-year relative survival rate of <5% [2] . Besides tobacco smoking, other recognized risk factors are overweight/obesity, high alcohol consumption, history of pancreatitis and diabetes, family history of pancreatic cancer, and possibly selected dietary factors [3] .
Type 2 diabetes mellitus has been associated with an excess risk of pancreatic cancer in a number of epidemiological studies [4] [5] [6] [7] [8] [9] . The excess risk has been shown to be greater for a recent diagnosis of diabetes and to decline with increasing time since diagnosis, thus supporting the hypothesis that diabetes may be -at least in part-a consequence or an early manifestation of the disease. However, some increased risks for pancreatic cancer have been reported among individuals who had diabetes for 10 or more years [5, 7, 10, 11] , indicating that diabetes may also play a causal role in pancreatic carcinogenesis.
Diabetes medications may also influence the risk of pancreatic cancer, although epidemiologic data are scanty. In particular, it has been reported that insulin might further increase pancreatic cancer risk, metformin might reduce it [6, 12] , while sulfonylureas [12] or thiazolidinediones [13] have no consistent role on pancreatic cancer.
The availability of a large dataset within the Pancreatic Cancer Case-Control Consortium (PanC4; http://www.panc4.org) gave a unique opportunity to further investigate the association of diabetes and its medications with the risk of pancreatic cancer.
methods
The present pooled analysis included 8305 cases of adenocarcinoma of the exocrine pancreas and 13 987 controls from 15 case-control studies within the PanC4 consortium, providing information on history of diabetes and medications for diabetes [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . The main characteristics of the studies are described in supplementary Table S1 , available at Annals of Oncology online. In most studies, cases and controls were interviewed or surveyed in-person, with the exception of 537 cases (6.5%) and 332 of controls (2.4%).
The original datasets were restructured either by the study investigators or by our central coordinators using a uniform format for data harmonization.
From each study, we collected individual data on sociodemographic factors, study characteristics, anthropometric measures, tobacco smoking, alcohol consumption, and history of pancreatitis. History of diabetes was based on selfreported information from questionnaire and included age at first diagnosis. Some of the studies provided additional information on diabetes medications (see supplementary Text S1, available at Annals of Oncology online for details).
statistical analysis
To estimate the association between diabetes, antidiabetics and pancreatic cancer, we conducted an aggregate analysis pooling individual-level data from all the PanC4 studies into a single dataset, and we computed pooled odds ratios (ORs) and the corresponding 95% confidence intervals (CIs), using unconditional logistic regression models [29] . These included terms for study, center (for multicenter studies), age, sex, education, race/ethnicity, body mass index (BMI), tobacco, alcohol consumption, and history of pancreatitis. Dummy variables were used in all analyses for variables with missing data. Study-specific and pooled ORs and corresponding 95% CIs were also plotted for visual comparison. We investigated whether the effect of history of diabetes was homogeneous in strata of selected covariates by conducting stratified analyses. We also carried out sensitivity analyses excluding proxy-respondents and participants with a history of pancreatitis.
results
Cases and controls had similar distributions by sex and alcohol consumption; cases were somewhat older than controls, had a higher level of education, were more frequently obese, white and ever smokers, and reported a history of pancreatitis more frequently (supplementary Table S2 , available at Annals of Oncology online).
Overall, 1767 (21%) cases and 1284 (9%) controls reported a history of diabetes, corresponding to an OR of 2.39 (95% CI 2.19-2.61); 1155 (15%) cases and 1087 (8%) controls had a history of diabetes 2 or more years before cancer diagnosis (or interview), with a corresponding OR of 1.90 (95% CI 1.72-2.09, Table 1 ). Significant heterogeneity between study results was observed, the ORs varying between 1.3 and 6.0 (Figure 1 ). Pancreatic cancer risk decreased with a duration of diabetes, but a 54% excess risk was still evident 15 to <20 years since diabetes diagnosis and a 30% excess risk 20 or more years since diabetes diagnosis ( Risk estimates for a diagnosis of diabetes 2 or more years before cancer diagnosis/interview were consistent across strata of sex, age, race/ethnicity, education, BMI, tobacco smoking, and study areas, whereas they were slightly higher in no/low drinkers (OR 2.09) than in moderate (OR 1.79) and high (OR 1.57) drinkers, and in hospital-based (OR 2.55) than in population-based (OR 1.50) studies (Table 2 ). For diabetes diagnoses <2 years before cancer diagnosis/interview, risk estimates were consistent across the strata of most covariates considered, but they were significantly higher in men (OR 7.14) than in women (OR 4.86), in those with higher (OR 9.05) than lower (OR 4.53) level of education, and in hospital-based (OR 7.98) than in population-based (OR 4.52) studies. The ORs for diabetes 2 or more years before cancer diagnosis/interview were 1.91 (95% CI 1.73-2.12) when we excluded proxy-respondents and 1.64 (95% CI 1.46-1.84) when we excluded participants with a history of pancreatitis (data not shown).
Diabetics using oral antidiabetics had a nonsignificant reduced risk of pancreatic cancer when compared with those not using them (OR 0.92, Table 3 ). The OR decreased with an increasing duration of oral antidiabetic use and was 0.31 for ≥15 years of use. The risk was significantly higher in diabetics who used insulin (OR 2.66) when compared with those not using insulin; it was higher for a shorter insulin use (OR 5.60, for <5 years of use) and declined with an increasing duration of use (OR 0.95, for ≥15 years of use). Risk estimates did not meaningfully change when we mutually adjusted the use of oral antidiabetics and insulin, nor when we adjusted oral antidiabetic and insulin use for the duration of diabetes.
discussion
This collaborative analysis-including data on more than 8000 pancreatic cancer cases-confirms that diabetics have an almost twofold increased risk of developing pancreatic cancer and provides more definitive and precise estimates than previously available [5, 7, 9] .
About 30% of diabetics in the present study had a diagnosis of diabetes close to the time of their pancreatic cancer diagnosis and the excess risk in those individuals was particularly high [5, 7] . Although the risk of pancreatic cancer tended to decline with an increasing duration of diabetes, we found that a [5, 7, 9] showed a 30%-50% increased risk of pancreatic cancer among patients who had diabetes for 10 or more years, but they were not able to estimate a pancreatic cancer risk for longer duration of diabetes. All studies provided risk estimates above unity, but significant heterogeneity between them was observed. In particular, higher excess risk was observed in the Greece, Italy, Mayo Clinic, and University of Minnesota studies, that had a low prevalence of diabetes among controls.
The mechanisms underlying the relationship between diabetes and pancreatic cancer are complex [8, 30] . The excess pancreatic cancer risk for a recent diagnosis of diabetes is compatible with the hypothesis that diabetes is, at least in part, an early manifestation or a consequence of pre-clinical pancreatic cancer [31] [32] [33] . Pancreatic cancer has been shown to cause diabetes, the so-called Type 3c diabetes, by inducing beta-cell dysfunction and peripheral insulin resistance, suppressing insulin secretion, and impairing proinsulin conversion [34] [35] [36] . Diabetesinduced by pancreatic cancer is usually resolved after pancreatic tumor resection [32, 37] . Early symptoms of pancreatic cancer may also favor the diagnosis of diabetes (or vice versa), thus partly explaining the excess risk in patients with a recent diagnosis of diabetes. To reduce the possibility of reverse causation or diagnostic bias, we have focused our analyses on diabetes diagnosed 2 or more years before cancer diagnosis.
The increased pancreatic cancer risk observed 5, 10, and up to 20 or more years since diagnosis of diabetes cannot be due to reverse causation or diagnostic bias and supports causal role of diabetes on pancreatic cancer. Diabetes is associated with hyperglycemia, insulin resistance, compensatory hyperinsulinemia, and up-regulated levels of insulin-like growth factors (IGFs) [8, 38] . Peripheral insulin resistance 5 or 10 years before pancreatic cancer diagnosis has been related to an increased pancreatic cancer risk [39] . High insulin concentrations may directly be involved in the etiology of pancreatic cancer, as insulin is a growth promoter and mitogen in pancreatic cell lines [40, 41] . Moreover, IGF-1 and its receptors can decrease apoptosis and increase proliferation, invasion, and angiogenesis [42] , and possibly increase pancreatic cancer risk [43] . The association between diabetes and pancreatic cancer might also be mediated by obesity-one of the major determinants of Type 2 diabetes mellitus and a known risk factor for pancreatic cancer [44] . Study-specific ORs were computed from logistic regression models adjusted for center (for multicenter studies), age, sex, race/ ethnicity, education, body mass index, tobacco smoking, alcohol drinking (except for the MSKCC study), and history of pancreatitis (except for the Italy, Mayo Clinic, and Penn State studies). Pooled ORs were further adjusted for study. Homogeneity of ORs between studies was based on likelihood ratio tests and the resulting χ However, the consistent risks observed across strata of BMI indicate that obesity is unlikely explain the observed association. We found that pancreatic cancer risk was increased, although weakly and not significantly, among diabetics who were diagnosed with diabetes before 30 years of age. This provides support for a possible role of Type 1 diabetes in pancreatic carcinogenesis [45] . However, the number of early-onset diabetics is too limited to draw any definitive conclusion.
We observed a nonsignificant reduced risk of pancreatic cancer in diabetics using oral antidiabetics, the risk decreasing with longer duration of use. Conversely, the risk was elevated among insulin users and particularly in those with a shorter duration of use. Although the duration of antidiabetics use is likely to mirror the time between diabetes diagnosis and cancer diagnosis/interview, the addition of a term for the duration of diabetes in the models did not meaningfully affect our risk estimates. A few previous studies-most of them included in our pooled-analysis-reported a lower pancreatic cancer risk in diabetics using oral antidiabetics than in those using insulin [10, 12, 16, 18, 21, 28, 46] . Metformin, in particular, has been associated with a reduced risk of ( pancreatic) cancer [12] , the favorable effect being mediated by both its ability to lower glycemic and insulin levels and to its tumor growth inhibitory activity [12, 47] . However, the lower severity of diabetes and variable baseline characteristics of patients using oral antidiabetic drugs may have influenced this association. Similarly, although insulin may directly increase pancreatic cancer risk [41] , the excess risk for shorter-term insulin use in the absence of a risk-duration relationship indicates that such excess risk in insulin users is likely explained by reverse causation. Insulin, in fact, tends to be prescribed in patients with more advanced diseases and its shortterm excess risk may be due to a progressive worsening of diabetes after pancreatic cancer [48] . This PanC4 collaborative study has a number of strengths. These include the uniquely large dataset, the detailed information from most studies on diabetes and on antidiabetic medications, and the ability to account uniformly and carefully for study design variables and major recognized confounding factors. However, information on alcohol drinking and history of pancreatitis was not available in a few studies and this may have contributed to the heterogeneity between studies. Moreover, the large available dataset allowed us to show that risk estimates were consistent across strata of various covariates, including tobacco smoking and BMI. Among the limitations of our study is that history of diabetes was self-reported. However, diabetes is a serious chronic condition and it has been reliably recalled in other epidemiological studies [49, 50] . Furthermore, it is possible that self-reported information on medical conditions is reported more accurately in cases than in population-controls, but not necessarily in hospital-controls [49] . Furthermore, our risk estimates are consistent with those provided by cohort studies [4, 5, 7, 9] , arguing against a major role of recall or a selection bias. Accuracy of medical information may also be different between in-person and proxy-respondents, although proxy-respondents were a small minority of the total dataset and restriction of our analyses to in-person respondents yielded similar results. We could not distinguish between Type 1 and Type 2 diabetes, but 97% of our diabetic patients were diagnosed after 30 years of age and were thus likely to be affected by Type 2 diabetes. Finally, medication history was also selfreported, and, in almost all studies, we had no information of the specific types of oral antidiabetic used.
acknowledgements
